| 000 | 01406nam a2200361 c 4500 | ||
|---|---|---|---|
| 005 | 20250919122249.0 | ||
| 008 | 180704 2017 si a 001 0 eng | ||
| 020 |
_a9789811035081 _cRM543.73 |
||
| 039 | 9 |
_a201810121105 _bazriq _c201810121105 _dazriq _c201810021601 _dsalmah _y07-04-2018 _zadilla |
|
| 040 |
_dUKM _erda |
||
| 090 | _aWK835.S849d 2017 9HUKM | ||
| 090 |
_aWK835 _b.S849d 2017 9HUKM |
||
| 100 | 1 |
_aStewart, Michael W., _eauthor. |
|
| 245 | 1 | 0 |
_aDiabetic retinopathy : _bcurrent pharmacologic treatment and emerging strategies / _cMichael W. Stewart. |
| 264 | 4 |
_aSingapore : _bADIS, _c[2017], ©2017. |
|
| 300 |
_axiii, 268 pages : _billustrations ; _c24 cm. |
||
| 336 |
_atext _2rdacontent |
||
| 337 |
_aunmediated _2rdamedia |
||
| 338 |
_avolume _2rdacarrier |
||
| 504 | _aIncludes bibliographical references. | ||
| 650 | 2 |
_aDiabetic Retinopathy _xdrug therapy. |
|
| 650 | 2 |
_aDiabetic Retinopathy _xphysiopathology. |
|
| 650 | 2 |
_aAngiogenesis Inhibitors _xtherapeutic use. |
|
| 650 | 2 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors. |
|
| 907 |
_a.b16600848 _b2019-11-12 _c2019-11-12 |
||
| 942 |
_c01 _n0 _kWK835.S849d 2017 9HUKM |
||
| 914 | _avtls003635239 | ||
| 990 | _aadilla/azriq | ||
| 991 | _aJabatan Oftalmologi, PPUKM. | ||
| 998 |
_ah _b2018-04-07 _cm _da _feng _gsi _y0 _z.b16600848 |
||
| 999 |
_c628452 _d628452 |
||